Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

The makers of weight-loss drug Mounjaro have said that they will work with health authorities to “find solutions” after the ...

Vertex Pharmaceuticals Incorporated ( VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM EST ...

For some, it’s the joy of helping customers and colleagues. For others, satisfaction comes from feeling like the company ‘invests in my future.’ ...

Academic aid from employers includes help mapping out college finances, finding scholarship applications, getting your child ...

Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has caught the eye of Citi analyst Geoff Meacham, who has reiterated a Buy rating on the company’s stock. Meacham’s bullish outlook is largely driven ...